The pivotal trial was designed to evaluate the efficacy and safety of Zuragen for the prevention and treatment of catheter-related bloodstream infection (CRBSI) in end-stage renal disease patients requiring the use of a tunneled central venous catheter for hemodialysis compared to heparin, the current standard of care.
The trial enrolled 415 patients at 25 dialysis facilities across the US. Portions of the Azeptic trial were financed through grants awarded by the National Institutes of Health (NIH) and the Indiana 21st Century Research and Technology Fund.